Iglarz M - Search Results

1

The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation.

Steven S, Oelze M, Hausding M, Roohani S, Kashani F, Kröller-Schön S, Helmstädter J, Jansen T, Baum C, Iglarz M, Schulz E, Münzel T, Daiber A. Steven S, et al. Among authors: iglarz m. Oxid Med Cell Longev. 2018 Dec 27;2018:7845629. doi: 10.1155/2018/7845629. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 30687454 Free PMC article.

2

Mechanisms of ET-1-induced endothelial dysfunction.

Iglarz M, Clozel M. Iglarz M, et al. J Cardiovasc Pharmacol. 2007 Dec;50(6):621-8. doi: 10.1097/FJC.0b013e31813c6cc3. J Cardiovasc Pharmacol. 2007. PMID: 18091577 Review.

3

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.

Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B, Hess P, Qiu C, Clozel M. Iglarz M, et al. J Pharmacol Exp Ther. 2008 Dec;327(3):736-45. doi: 10.1124/jpet.108.142976. Epub 2008 Sep 9. J Pharmacol Exp Ther. 2008. PMID: 18780830

4

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.

Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, Iglarz M, Meyer S, Rein J, Rey M, Treiber A, Clozel M, Fischli W, Weller T. Bolli MH, et al. Among authors: iglarz m. J Med Chem. 2012 Sep 13;55(17):7849-61. doi: 10.1021/jm3009103. Epub 2012 Aug 16. J Med Chem. 2012. PMID: 22862294

5

Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.

Iglarz M, Bossu A, Wanner D, Bortolamiol C, Rey M, Hess P, Clozel M. Iglarz M, et al. Life Sci. 2014 Nov 24;118(2):333-9. doi: 10.1016/j.lfs.2014.02.018. Epub 2014 Feb 26. Life Sci. 2014. PMID: 24582812 Free article.

6

Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.

Iglarz M, Steiner P, Wanner D, Rey M, Hess P, Clozel M. Iglarz M, et al. J Cardiovasc Pharmacol. 2015 Oct;66(4):332-7. doi: 10.1097/FJC.0000000000000283. J Cardiovasc Pharmacol. 2015. PMID: 25992919 Free PMC article.

7

Endothelin receptor antagonist macitentan or deletion of mouse mast cell protease 4 delays lesion development in atherosclerotic mice.

Houde M, Desbiens L, Schwertani A, Pejler G, Iglarz M, D'Orléans-Juste P. Houde M, et al. Among authors: iglarz m. Life Sci. 2016 Aug 15;159:71-75. doi: 10.1016/j.lfs.2016.03.018. Epub 2016 Mar 12. Life Sci. 2016. PMID: 26976326

8

Endothelin ET_A Receptor Blockade, by Activating ET_B Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention.

Vercauteren M, Trensz F, Pasquali A, Cattaneo C, Strasser DS, Hess P, Iglarz M, Clozel M. Vercauteren M, et al. Among authors: iglarz m. J Pharmacol Exp Ther. 2017 May;361(2):322-333. doi: 10.1124/jpet.116.234930. Epub 2017 Feb 21. J Pharmacol Exp Ther. 2017. PMID: 28223322

9

Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.

Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C. Clozel M, et al. Among authors: iglarz m. Exp Biol Med (Maywood). 2006 Jun;231(6):967-73. Exp Biol Med (Maywood). 2006. PMID: 16741032

10

At the heart of tissue: endothelin system and end-organ damage.

Iglarz M, Clozel M. Iglarz M, et al. Clin Sci (Lond). 2010 Aug 17;119(11):453-63. doi: 10.1042/CS20100222. Clin Sci (Lond). 2010. PMID: 20712600 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page